Cancer Pain Therapeutics

Cancer Pain Therapeutics Market Outlook

The global cancer pain therapeutics market is projected to reach USD 12.3 billion by 2035, growing at a CAGR of 6.2% from 2025 to 2035. This growth can be attributed to an increasing prevalence of cancer and chronic pain conditions, as well as advancements in drug formulations and treatment modalities. Moreover, the rising awareness of pain management protocols among healthcare providers and patients is significantly driving the demand for effective therapeutic options. The influx of innovative therapies in the market, along with supportive government initiatives and funding, contributes to an enhanced understanding of cancer pain management. Additionally, an aging population, which is more susceptible to cancer, is further propelling market growth as the demand for tailored pain relief therapies increases.

Growth Factor of the Market

The cancer pain therapeutics market is primarily driven by the rising incidence of cancer worldwide, necessitating effective pain management solutions. The growing focus on personalized medicine and the development of targeted therapies are also facilitating improvements in treatment outcomes for cancer patients experiencing pain. Moreover, advancements in drug delivery systems and formulations have made pain relief more effective, encouraging healthcare providers to adopt these therapies. The increasing number of clinical trials aimed at developing new analgesics specifically for cancer pain is another significant growth factor in this market. Additionally, the evolving healthcare infrastructure and increasing investment in research and development further bolster the demand for more effective and safe cancer pain management options.

Key Highlights of the Market

• Significant rise in the number of cancer cases leading to increased demand for pain management therapies.
• Innovations in drug formulations and delivery systems are enhancing treatment efficacy.
• Growth of online pharmacies is improving accessibility to cancer pain therapeutics.
• Increasing collaborations between pharmaceutical companies and research institutions.
• Rising awareness among healthcare professionals regarding pain management protocols.

By Drug Class

Opioids:

Opioids are considered the cornerstone of cancer pain management and hold a significant share of the market due to their high efficacy in alleviating moderate to severe pain. The development of new formulations, such as extended-release opioids, is enhancing their effectiveness while minimizing the risks of addiction. Despite concerns regarding opioid abuse, their clinical utility in cancer pain management remains undeniable, prompting healthcare providers to continue prescribing them. Moreover, ongoing research is focusing on optimizing opioid use through combination therapies, thereby reducing side effects while enhancing pain relief. As such, the opioid segment is expected to maintain a dominant position in the cancer pain therapeutics market in the coming years.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs):

Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for managing mild to moderate cancer pain, particularly those related to inflammation. As they offer analgesic, anti-inflammatory, and antipyretic properties, their multi-faceted action makes them a popular choice for initial pain management in cancer patients. The availability of both prescription and over-the-counter NSAIDs adds to their accessibility for patients. Furthermore, ongoing developments in formulation, such as topical NSAIDs, are providing additional options for localized pain relief with reduced systemic side effects. The growth in the NSAID segment is expected to be sustained by the increasing recognition of their role in multimodal pain management strategies.

Antidepressants:

Antidepressants have emerged as an effective option for managing neuropathic pain in cancer patients, particularly when conventional pain relief methods are insufficient. Their dual role in treating both depression and pain enhances the quality of life for patients undergoing cancer treatment. Research indicates that certain classes of antidepressants, such as tricyclic antidepressants and SNRIs, can significantly alleviate cancer-related pain, especially in cases of neuropathy and mood disorders. As awareness of the psychological aspects of cancer pain management continues to grow, the utilization of antidepressants is expected to rise, thus contributing to the overall expansion of the cancer pain therapeutics market.

Anticonvulsants:

Anticonvulsants are increasingly being recognized for their role in treating neuropathic pain associated with cancer. Medications such as gabapentin and pregabalin have shown promising results in alleviating pain by modulating neurotransmitter release and reducing neuronal excitability. Their use in cancer pain management is particularly valuable for patients experiencing nerve-related pain or side effects from chemotherapy agents. As clinicians continue to explore combination therapies that include anticonvulsants for more comprehensive pain management, the segment is expected to gain traction in the market. The increasing recognition of neuropathic pain as a significant component of cancer pain will further support the growth of this segment.

Others:

The "Others" segment of the cancer pain therapeutics market encompasses a variety of alternative treatments and adjunct therapies, including corticosteroids, cannabinoids, and non-pharmacological interventions. These therapies are often utilized in conjunction with traditional pain management methods to enhance overall efficacy and improve patient outcomes. For instance, cannabinoids have gained attention for their potential to alleviate pain and reduce chemotherapy-induced nausea. The growing acceptance of integrative medicine and alternative therapies is expected to fuel demand in this category, as patients and healthcare providers increasingly seek holistic approaches to cancer pain management.

By Cancer Type

Breast Cancer:

Breast cancer is one of the most prevalent cancer types globally, leading to significant pain management needs among affected individuals. The pain experienced by breast cancer patients can arise from the disease itself, surgical interventions, and subsequent treatments such as chemotherapy and radiation. As a result, there is a high demand for effective pain management solutions tailored to this demographic. The increasing focus on personalized treatment approaches in breast cancer care, alongside the development of targeted therapeutics, is expected to drive the market for cancer pain therapeutics in this segment. Moreover, the growing awareness surrounding the importance of pain management in improving the quality of life for breast cancer survivors further supports market growth.

Lung Cancer:

Lung cancer is associated with significant pain, primarily due to the invasive nature of the disease and its treatments. Patients with lung cancer can experience pain from tumor growth, metastasis, and complications arising from treatment modalities such as surgery, chemotherapy, and radiotherapy. The need for effective pain management strategies is crucial to enhance patient comfort and overall treatment outcomes. As the incidence of lung cancer continues to rise globally, the demand for tailored cancer pain therapeutics is expected to increase as well. Efforts to develop new analgesic agents specifically designed for lung cancer pain are likely to gain traction, further propelling the market in this segment.

Prostate Cancer:

Prostate cancer is one of the most common cancers affecting men, leading to various pain types, including bone pain and treatment-related discomfort. Pain management is a critical component of prostate cancer care, particularly in advanced stages of the disease when metastasis occurs. The increasing incorporation of multidisciplinary approaches in managing prostate cancer pain, including pharmacological and non-pharmacological therapies, is likely to fuel growth in this segment. Moreover, the growing emphasis on patient-centric approaches and improved healthcare access for men is expected to drive the demand for effective cancer pain therapeutics, ensuring that patients receive comprehensive pain relief as part of their care regimen.

Colorectal Cancer:

Colorectal cancer can result in significant pain due to tumor growth, treatment complications, and surgical interventions. Pain management is vital for enhancing the quality of life for colorectal cancer patients, particularly during the treatment phase. As the incidence of colorectal cancer rises due to lifestyle factors and an aging population, the demand for effective pain management solutions is expected to increase. Furthermore, advancements in treatment protocols and the recognition of the importance of addressing pain in colorectal cancer care are likely to drive the adoption of various pharmacological options for pain relief. This indicates a growing market for cancer pain therapeutics focused on this specific cancer type.

Others:

The "Others" segment in cancer types includes various malignancies that also contribute to the overall demand for cancer pain therapeutics. This segment encompasses a diverse range of cancer types, such as pancreatic cancer, liver cancer, and gynecological cancers, all of which can result in significant pain and discomfort for patients. The heterogeneity of pain experiences among patients with different cancer types necessitates tailored pain management strategies, leading to an increasing focus on developing therapies that cater to these unique needs. As awareness of the importance of pain management in improving cancer patient outcomes continues to grow, this segment is expected to contribute to the overall expansion of the cancer pain therapeutics market.

By Therapy Type

Chemotherapy-Induced Pain:

Chemotherapy-induced pain is a significant concern for many cancer patients undergoing treatment. Often, chemotherapy can lead to a variety of painful side effects, including neuropathic pain, mucositis, and visceral pain. As the incidence of cancer diagnoses continues to rise, the demand for effective management of chemotherapy-related pain is expected to grow. Treatments in this category often involve a multi-modal approach, combining pharmacological therapies such as analgesics and adjunctive medications like anticonvulsants and antidepressants. Moreover, the increasing emphasis on patient comfort and quality of life during cancer treatment will continue to support market growth in this segment.

Surgery-Related Pain:

Surgery-related pain is a common occurrence among cancer patients, particularly following invasive procedures such as tumor resections or organ removal. Effective management of postoperative pain is critical to facilitate recovery and improve the overall patient experience. As surgical techniques advance and minimally invasive methods become more prevalent, the pain management strategies utilized are also evolving. The increasing focus on enhancing the quality of surgical care, coupled with the development of pain management protocols that include both pharmacological and non-pharmacological interventions, is expected to drive growth in this segment. Healthcare providers are increasingly recognizing the importance of comprehensive pain management strategies to minimize surgery-related discomfort in cancer patients.

Bone Pain:

Bone pain is a common and debilitating symptom in cancer patients, particularly those with metastatic disease. Pain originating from bone metastases can significantly impact a patient's quality of life and functional abilities. The management of bone pain often requires a combination of systemic therapies, including opioids, NSAIDs, and radiation therapy. With the growing recognition of the importance of addressing bone pain as a component of cancer care, there is an increasing demand for effective therapeutic options in this segment. Furthermore, advancements in treatment modalities, such as bisphosphonates and denosumab, are providing additional avenues for alleviating bone pain, contributing to market growth.

Neuropathic Pain:

Neuropathic pain is a significant aspect of cancer pain that can arise from nerve damage due to tumor compression or chemotherapy-induced neurotoxicity. This type of pain can be particularly challenging to manage, necessitating specialized pain management strategies. The growing understanding of the mechanisms underlying neuropathic pain is leading to the development of targeted therapies, including anticonvulsants and antidepressants, which are increasingly being adopted in clinical practice. As the prevalence of neuropathic pain in cancer patients is recognized, the demand for effective management solutions is anticipated to rise, driving growth in this segment of the cancer pain therapeutics market.

Others:

The "Others" category of therapy types encompasses various pain management strategies and modalities that do not fit into the traditional classifications. This includes integrative therapies such as acupuncture, physical therapy, and psychological interventions, all of which play a role in alleviating cancer-related pain. With the growing acceptance of holistic approaches to healthcare, there is increasing interest in combining these complementary therapies with conventional pain management strategies. As healthcare providers continue to explore innovative solutions to enhance patient comfort and quality of life, this segment is expected to see growth in demand for diverse pain management options.

By Distribution Channel

Hospitals:

Hospitals play a critical role in the distribution of cancer pain therapeutics, serving as primary care facilities for patients undergoing treatment. In-hospital pharmacies are equipped to provide a range of analgesics and adjunct therapies tailored to individual patient needs. The presence of specialized oncology units within hospitals enhances the capacity for personalized pain management, ensuring that patients receive timely and effective relief. Moreover, the ongoing developments in hospital protocols for pain management, including guidelines for assessing and addressing cancer pain, are likely to further solidify the hospital distribution channel's significance in the market.

Retail Pharmacies:

Retail pharmacies are a vital distribution channel for cancer pain therapeutics, providing patients with access to prescribed medications and over-the-counter pain relief options. As patients often seek to manage their pain on an outpatient basis, retail pharmacies play a crucial role in ensuring medication accessibility. The growing trend towards patient empowerment and self-management of health conditions is further enhancing the significance of retail pharmacies in the cancer pain therapeutics market. Additionally, the increasing collaboration between healthcare providers and pharmacists is facilitating better patient education and adherence to pain management plans, ultimately contributing to improved patient outcomes.

Online Pharmacies:

The rise of online pharmacies has transformed the landscape of medication distribution, offering convenience and accessibility for patients seeking cancer pain therapeutics. With the increasing adoption of telemedicine and digital health solutions, online pharmacies provide an efficient platform for patients to obtain their medications without the need for in-person visits. This is especially beneficial for individuals undergoing cancer treatment who may experience mobility challenges or wish to maintain their privacy. Moreover, the growing trend of e-commerce in healthcare is expected to drive the growth of online pharmacies in the cancer pain therapeutics market, as patients increasingly turn to digital solutions for their healthcare needs.

Others:

The "Others" category in distribution channels includes various niche players and alternative avenues for delivering cancer pain therapeutics. This may encompass specialty pharmacies, home healthcare services, and distributors focusing on specific therapeutic areas. These alternative distribution methods can enhance patient access to pain management solutions, particularly for those with unique needs or who require specialized formulations. As the landscape of cancer pain management continues to evolve, the importance of diverse distribution channels will become increasingly evident in ensuring that patients receive comprehensive care tailored to their specific circumstances.

By Region

The North American region holds a dominant share of the global cancer pain therapeutics market, driven by the high prevalence of cancer and advanced healthcare infrastructure. According to recent statistics, approximately 1.9 million new cancer cases are expected to be diagnosed in the United States alone in 2023, underscoring the immense need for effective pain management solutions. The United States is projected to account for over 35% of the global market share, supported by a robust pharmaceutical industry and a growing focus on improving cancer care outcomes. Additionally, with a CAGR of 6.5%, North America is expected to continue leading the market throughout the forecast period, fueled by ongoing innovations in drug development and patient-centric care initiatives.

In Europe, the market for cancer pain therapeutics is expanding due to an increasing aging population and a rise in cancer incidence rates. The European region is estimated to account for approximately 30% of the global market, with countries such as Germany, France, and the United Kingdom leading in terms of market share and growth. Efforts to improve healthcare access and awareness around pain management strategies are expected to contribute to the market’s growth in Europe. Furthermore, collaboration between public health institutions and pharmaceutical companies to develop effective pain management guidelines is likely to bolster the availability of cancer pain therapeutics in the region. As a result, both North America and Europe are set to experience sustained growth in the cancer pain therapeutics market.

Opportunities

The cancer pain therapeutics market presents numerous opportunities for growth, particularly in the area of innovative drug development. As research continues to advance our understanding of the underlying mechanisms of cancer pain, pharmaceutical companies are increasingly focusing on developing targeted therapies tailored to the specific needs of cancer patients. The advent of personalized medicine and the shift towards precision oncology are creating avenues for the development of more effective pain management solutions that can address the unique pain profiles of individual patients. Additionally, the integration of technology in pain management, such as digital health tools and telemedicine, is enhancing the accessibility and effectiveness of pain relief strategies.

Moreover, the global push for improved patient-centered care is driving the demand for comprehensive pain management approaches that encompass both pharmacological and non-pharmacological therapies. This growing emphasis on holistic care presents opportunities for stakeholders within the cancer pain therapeutics market to develop multi-modal treatment plans that incorporate alternative therapies such as acupuncture, cognitive behavioral therapy, and physical rehabilitation. Furthermore, collaborations between pharmaceutical companies, healthcare providers, and research institutions can lead to the discovery of new therapeutic targets, ultimately enhancing treatment options for cancer pain management.

Threats

While the cancer pain therapeutics market is poised for growth, it does face certain threats that can impede its progress. One of the primary challenges is the increasing scrutiny surrounding opioid use, as concerns over addiction and misuse have become more prevalent. Regulatory bodies are implementing stricter guidelines for opioid prescriptions, which may limit access to essential pain management therapies for cancer patients. This heightened regulatory environment can lead to uncertainties for pharmaceutical companies, impacting their ability to develop and market effective pain relief options. Additionally, the potential for negative public perception and stigma associated with opioid use can further complicate the therapeutic landscape, resulting in a more cautious approach to pain management practices.

Another significant threat is the prevalence of alternative and complementary therapies that may compete with conventional cancer pain therapeutics. Patients are increasingly seeking non-pharmacological interventions, which can sometimes undermine the market for traditional pain management medications. Moreover, the lack of standardized guidelines for integrating these alternative therapies into conventional care can create confusion among patients and healthcare providers, potentially affecting adherence to prescribed pain management plans. As the landscape of cancer pain management continues to evolve, stakeholders must navigate these challenges to ensure the continued provision of effective therapeutic options.

Competitor Outlook

• Pfizer Inc.
• Johnson & Johnson
• AbbVie Inc.
• Merck & Co., Inc.
• Teva Pharmaceutical Industries Ltd.
• Amgen Inc.
• Roche Holding AG
• Novartis AG
• Bristol-Myers Squibb Company
• GSK plc
• Horizon Therapeutics plc
• Celgene Corporation
• Regeneron Pharmaceuticals, Inc.
• Sanofi S.A.
• Eli Lilly and Company

The competitive landscape of the cancer pain therapeutics market is marked by the presence of several established pharmaceutical companies that are actively engaged in the development and marketing of pain management solutions. These companies are focusing on innovation, research, and strategic acquisitions to enhance their product offerings and strengthen their market position. The continuous advancements in drug formulations and delivery systems are encouraging companies to invest significantly in research and development initiatives aimed at improving the efficacy and safety profiles of their pain management therapies. Furthermore, collaborations with academic institutions and research organizations are becoming increasingly common, driving the discovery of novel analgesic agents tailored to the specific needs of cancer patients.

Among the key players, Pfizer Inc. stands out with its extensive portfolio of pain management therapies, including opioids and non-opioid alternatives. The company is actively involved in research aimed at addressing the complexities of cancer pain, emphasizing patient-centered approaches in their treatment protocols. Similarly, Johnson & Johnson has established itself as a leader in the field with its innovative range of analgesics and ongoing commitment to addressing the challenges surrounding cancer pain management. Their focus on enhancing patient outcomes through research collaborations and the development of novel therapies positions them favorably within the competitive landscape.

AbbVie Inc. is another prominent player, recognized for its advancements in pain management and commitment to improving the quality of life for cancer patients. The company’s strategic partnerships and acquisitions have bolstered its research capabilities, leading to the development of new therapies that cater to the specific needs of individuals suffering from cancer pain. Moreover, Amgen Inc. is actively pursuing research in the cancer pain domain, focusing on developing biologic therapies that can provide targeted pain relief. As the landscape of cancer pain therapeutics evolves, these companies are likely to continue playing a pivotal role in driving innovations and enhancing treatment options for patients in need.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 GSK plc
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Amgen Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Sanofi S.A.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Roche Holding AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Johnson & Johnson
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Merck & Co., Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Celgene Corporation
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Eli Lilly and Company
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Horizon Therapeutics plc
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Bristol-Myers Squibb Company
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Regeneron Pharmaceuticals, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Cancer Pain Therapeutics Market, By Drug Class
    • 6.1.1 Opioids
    • 6.1.2 Non-Steroidal Anti-Inflammatory Drugs
    • 6.1.3 Antidepressants
    • 6.1.4 Anticonvulsants
    • 6.1.5 Others
  • 6.2 Cancer Pain Therapeutics Market, By Cancer Type
    • 6.2.1 Breast Cancer
    • 6.2.2 Lung Cancer
    • 6.2.3 Prostate Cancer
    • 6.2.4 Colorectal Cancer
    • 6.2.5 Others
  • 6.3 Cancer Pain Therapeutics Market, By Therapy Type
    • 6.3.1 Chemotherapy-Induced Pain
    • 6.3.2 Surgery-Related Pain
    • 6.3.3 Bone Pain
    • 6.3.4 Neuropathic Pain
    • 6.3.5 Others
  • 6.4 Cancer Pain Therapeutics Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Cancer Pain Therapeutics Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Cancer Pain Therapeutics market is categorized based on

By Drug Class

• Opioids
• Non-Steroidal Anti-Inflammatory Drugs
• Antidepressants
• Anticonvulsants
• Others

By Cancer Type

• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Colorectal Cancer
• Others

By Therapy Type

• Chemotherapy-Induced Pain
• Surgery-Related Pain
• Bone Pain
• Neuropathic Pain
• Others

By Distribution Channel

• Hospitals
• Retail Pharmacies
• Online Pharmacies
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Pfizer Inc.
• Johnson & Johnson
• AbbVie Inc.
• Merck & Co., Inc.
• Teva Pharmaceutical Industries Ltd.
• Amgen Inc.
• Roche Holding AG
• Novartis AG
• Bristol-Myers Squibb Company
• GSK plc
• Horizon Therapeutics plc
• Celgene Corporation
• Regeneron Pharmaceuticals, Inc.
• Sanofi S.A.
• Eli Lilly and Company